Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alpha-2b plus ribavirin in hepatitis C cirrhosis
ChiCTR-OPN-14005561Phase 4Recruiting
- Sponsor
- 302 Hospital of the People's Liberation Army
- Start
- Nov 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection and Cirrhosis (2 arms), sponsored by 302 Hospital of the People's Liberation Army. Primary endpoints: HCV RNA undetectable rate and Histological improvement rate. Started Nov 2013; status: recruiting.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on ChiCTR-OPN-14005561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-14005561.